Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome

Publisher： Bentham Science Publishers

E-ISSN： 1875-6212|15|3|218-229

ISSN： 1570-1611

Source： Current Vascular Pharmacology, Vol.15, Iss.3, 2017-04, pp. : 218-229

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists

By  

Current Diabetes Reviews, Vol. 5, Iss. 4, 2009-11 ,pp. : 266-275

Bentham Science Publishers

Access to resources Recommend Favorite

Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy

By  

Current Diabetes Reviews, Vol. 12, Iss. 4, 2016-10 ,pp. : 403-413

Bentham Science Publishers

Access to resources Recommend Favorite

Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential

By Holst J.J.  

Trends in Endocrinology and Metabolism, Vol. 10, Iss. 6, 1999-08 ,pp. : 229-235

Elsevier

Access to resources Recommend Favorite

Effect of Glucagon-like Peptide-2 (GLP-2) on Diurnal SGLT1 Expression

By Ramsanahie Anthony   Berger Urs   Zinner Michael   Whang Edward   Rhoads David   Ashley Stanley  

Digestive Diseases and Sciences, Vol. 49, Iss. 11-12, 2004-11 ,pp. : 1731-1737

Springer Publishing Company

Access to resources Recommend Favorite

Glucagon-Like Peptide 1 and the Cardiovascular System

By  

Current Diabetes Reviews, Vol. 10, Iss. 5, 2014-09 ,pp. : 302-310

Bentham Science Publishers

Access to resources Recommend Favorite